{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:07:28Z","timestamp":1793689648961,"version":"4.5.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00735-2","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T07:04:32Z","timestamp":1753686272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical applications and diagnostic research of GFAP and NfL in MS and NMOSD: a meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"XueJuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingYi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoFeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"14","key":"735_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321.","journal-title":"Mult Scler."},{"issue":"6","key":"735_CR2","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","volume":"31","author":"KB Holroyd","year":"2020","unstructured":"Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol. 2020;31(6):462\u20138.","journal-title":"Curr Opin Ophthalmol"},{"key":"735_CR3","doi-asserted-by":"publisher","first-page":"105644","DOI":"10.1016\/j.msard.2024.105644","volume":"87","author":"K Koerbel","year":"2024","unstructured":"Koerbel K, Maiworm M, Schaller-Paule M, et al. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis. Mult Scler Relat Disord. 2024;87:105644.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"735_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40001-023-01631-4","volume":"29","author":"X Zheng","year":"2024","unstructured":"Zheng X, Yang J, Hou Y, et al. Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP). Eur J Med Res. 2024;29(1):51.","journal-title":"Eur J Med Res"},{"key":"735_CR5","doi-asserted-by":"publisher","first-page":"104662","DOI":"10.1016\/j.ebiom.2023.104662","volume":"93","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Thanei GA, Harp C, et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine. 2023;93:104662.","journal-title":"EBioMedicine"},{"issue":"3","key":"735_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse E, Schaedelin S, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023;80(3):287\u201397.","journal-title":"JAMA Neurol"},{"key":"735_CR7","doi-asserted-by":"publisher","first-page":"1480676","DOI":"10.3389\/fimmu.2024.1480676","volume":"15","author":"F Rodriguez-Jorge","year":"2024","unstructured":"Rodriguez-Jorge F, Fernandez-Velasco JI, Villarrubia N, et al. Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis. Front Immunol. 2024;15:1480676.","journal-title":"Front Immunol"},{"issue":"5","key":"735_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/acn3.51045","volume":"7","author":"S Thebault","year":"2020","unstructured":"Thebault S, Lee H, Bose G, et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann Clin Transl Neurol. 2020;7(5):767\u201375.","journal-title":"Ann Clin Transl Neurol"},{"key":"735_CR9","doi-asserted-by":"publisher","first-page":"1454474","DOI":"10.3389\/fimmu.2024.1454474","volume":"15","author":"R Sainz-Amo","year":"2024","unstructured":"Sainz-Amo R, Rodero RA, Monreal E, et al. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. Front Immunol. 2024;15:1454474.","journal-title":"Front Immunol"},{"issue":"4","key":"735_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00415-023-12135-w","volume":"271","author":"PP Arroyo","year":"2024","unstructured":"Arroyo PP, Munoz-Vendrell A, Leon MI, et al. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort. J Neurol. 2024;271(4):1599\u2013609.","journal-title":"J Neurol"},{"issue":"4","key":"735_CR11","doi-asserted-by":"publisher","first-page":"e194828","DOI":"10.1371\/journal.pone.0194828","volume":"13","author":"L Novakova","year":"2018","unstructured":"Novakova L, Axelsson M, Malmestrom C, et al. Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. PLoS One. 2018;13(4):e194828.","journal-title":"PLoS One"},{"issue":"5","key":"735_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/ene.13274","volume":"24","author":"I Hakansson","year":"2017","unstructured":"Hakansson I, Tisell A, Cassel P, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017;24(5):703\u201312.","journal-title":"Eur J Neurol"},{"key":"735_CR13","doi-asserted-by":"publisher","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","volume":"12","author":"X Chang","year":"2021","unstructured":"Chang X, Huang W, Wang L, et al. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies. Front Immunol. 2021;12:647618.","journal-title":"Front Immunol"},{"issue":"5","key":"735_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/jnc.15478","volume":"159","author":"C Liu","year":"2021","unstructured":"Liu C, Lu Y, Wang J, et al. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. J Neurochem. 2021;159(5):913\u201322.","journal-title":"J Neurochem"},{"issue":"5","key":"735_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA, et al. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Ann Neurol. 2021;89(5):895\u2013910.","journal-title":"Ann Neurol"},{"issue":"1","key":"735_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18(1):105.","journal-title":"J Neuroinflammation"},{"key":"735_CR17","doi-asserted-by":"publisher","first-page":"91631256","DOI":"10.1177\/17562864211054952","volume":"14","author":"TX Zhang","year":"2021","unstructured":"Zhang TX, Chen JS, Du C, et al. Longitudinal treatment responsiveness on plasma neurofilament light chain and glial fibrillary acidic protein levels in neuromyelitis optica spectrum disorder. Ther Adv Neurol Disord. 2021;14:91631256.","journal-title":"Ther Adv Neurol Disord"},{"key":"735_CR18","doi-asserted-by":"publisher","first-page":"996469","DOI":"10.3389\/fimmu.2022.996469","volume":"13","author":"R Liu","year":"2022","unstructured":"Liu R, Du S, Zhao L, et al. Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target. Front Immunol. 2022;13:996469.","journal-title":"Front Immunol"},{"key":"735_CR19","doi-asserted-by":"publisher","first-page":"667705","DOI":"10.3389\/fimmu.2021.667705","volume":"12","author":"M Radandish","year":"2021","unstructured":"Radandish M, Khalilian P, Esmaeil N. The Role of Distinct Subsets of Macrophages in the Pathogenesis of MS and the Impact of Different Therapeutic Agents on These Populations. Front Immunol. 2021;12:667705.","journal-title":"Front Immunol"},{"key":"735_CR20","doi-asserted-by":"publisher","first-page":"1011579","DOI":"10.3389\/fneur.2022.1011579","volume":"13","author":"G Fadda","year":"2022","unstructured":"Fadda G, Flanagan EP, Cacciaguerra L, et al. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol. 2022;13:1011579.","journal-title":"Front Neurol"},{"issue":"5","key":"735_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","volume":"258","author":"M Axelsson","year":"2011","unstructured":"Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol. 2011;258(5):882\u20138.","journal-title":"J Neurol"},{"issue":"2","key":"735_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","volume":"26","author":"H Hogel","year":"2020","unstructured":"Hogel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26(2):210\u20139.","journal-title":"Mult Scler"},{"issue":"3","key":"735_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","volume":"75","author":"R Takano","year":"2010","unstructured":"Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010;75(3):208\u201316.","journal-title":"Neurology"},{"key":"735_CR24","doi-asserted-by":"publisher","first-page":"102870","DOI":"10.1016\/j.msard.2021.102870","volume":"51","author":"M Sun","year":"2021","unstructured":"Sun M, Liu N, Xie Q, et al. A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis. Mult Scler Relat Disord. 2021;51:102870.","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"735_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.47936\/encephalitis.2022.00101","volume":"3","author":"JS Kim","year":"2023","unstructured":"Kim JS. Protein biomarkers in multiple sclerosis. Encephalitis. 2023;3(2):54\u201363.","journal-title":"Encephalitis"},{"key":"735_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.cca.2013.03.020","volume":"421","author":"A Uzawa","year":"2013","unstructured":"Uzawa A, Mori M, Sawai S, et al. Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta. 2013;421:181\u20133.","journal-title":"Clin Chim Acta"},{"key":"735_CR27","doi-asserted-by":"publisher","first-page":"5381239","DOI":"10.1155\/2018\/5381239","volume":"2018","author":"Y Wei","year":"2018","unstructured":"Wei Y, Chang H, Li X, et al. CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders. Biomed Res Int. 2018;2018:5381239.","journal-title":"Biomed Res Int"},{"issue":"13","key":"735_CR28","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","volume":"93","author":"M Watanabe","year":"2019","unstructured":"Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology. 2019;93(13):e1299\u2013311.","journal-title":"Neurology"},{"issue":"6","key":"735_CR29","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/jnnp-2019-322286","volume":"91","author":"I Kleerekooper","year":"2020","unstructured":"Kleerekooper I, Herbert MK, Kuiperij HB, et al. CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. J Neurol Neurosurg Psychiatry. 2020;91(6):605\u201311.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"735_CR30","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/acn3.51070","volume":"7","author":"EJ Lee","year":"2020","unstructured":"Lee EJ, Lim YM, Kim S, et al. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol. 2020;7(6):992\u20131001.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"735_CR31","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/brain\/awab102","volume":"144","author":"Y Takai","year":"2021","unstructured":"Takai Y, Misu T, Suzuki H, et al. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders. Brain. 2021;144(8):2401\u201315.","journal-title":"Brain"},{"issue":"1","key":"735_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","volume":"19","author":"P Schindler","year":"2023","unstructured":"Schindler P, Aktas O, Ringelstein M, et al. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol. 2023;19(1):71\u201391.","journal-title":"Expert Rev Clin Immunol"},{"key":"735_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.msard.2019.02.009","volume":"30","author":"L Peng","year":"2019","unstructured":"Peng L, Bi C, Xia D, et al. Increased cerebrospinal fluid neurofilament light chain in central nervous system inflammatory demyelinating disease. Mult Scler Relat Disord. 2019;30:123\u20138.","journal-title":"Mult Scler Relat Disord"},{"key":"735_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler P, Grittner U, Oechtering J, et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation. 2021;18:105.","journal-title":"J Neuroinflammation"},{"key":"735_CR35","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1007\/s00415-024-12389-y","volume":"271","author":"I Rosenstein","year":"2024","unstructured":"Rosenstein I, Nordin A, Sabir H, et al. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis. J Neurol. 2024;271:4412\u201322.","journal-title":"J Neurol"},{"key":"735_CR36","doi-asserted-by":"publisher","first-page":"10381","DOI":"10.1038\/s41598-020-67504-6","volume":"10","author":"S Thebault","year":"2020","unstructured":"Thebault S, Abdoli M, Fereshtehnejad SM, et al. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci Rep. 2020;10:10381.","journal-title":"Sci Rep"},{"issue":"1","key":"735_CR37","doi-asserted-by":"publisher","first-page":"e200188","DOI":"10.1212\/NXI.0000000000200188","volume":"11","author":"S Carta","year":"2024","unstructured":"Carta S, Dinoto A, Capobianco M, et al. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(1):e200188.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"735_CR38","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","volume":"7","author":"H Kim","year":"2020","unstructured":"Kim H, Lee EJ, Kim S, et al. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm. 2020;7(3):e708.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00735-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00735-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00735-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T03:55:16Z","timestamp":1757303716000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00735-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["735"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00735-2","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). As this study involves the summary and analysis of other studies, it does not involve medical ethics approval or patient-informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}